SeekingAlpha · Sep 25, 2026
LENZ Therapeutics: Below Cash For A Reason
LENZ Therapeutics, Inc. trades below cash, but weak demand, high burn, and single-asset risk threaten its runway. Read the latest analysis on LENZ stock here.
LE
NASDAQ · LENZ
LENZ Therapeutics, Inc.
Healthcare · Biotechnology
$3.30
Down-$0.11 (-3.33%)
Updated Oct 20, 2026, 11:35 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 684.09M
- P/E ratio
- -13.13
- Dividend yield
- 0.00%
- 52-week range
- $3.21 – $32.92
- Volume
- 648.61K
- Avg. volume
- 997.98K
Price performance · LENZ
LENZ price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 19, 2026
LENZ closed at $3.30 after 21 trading sessions, down 19.12% for the selected period.
- Last close
- $3.30
- Period change
- -19.12%
- Period low
- $3.27
- Period high
- $4.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | $3.27 | $3.40 | $3.209 | $3.30 | 648.61K |
| Oct 16, 2026 | $3.56 | $3.56 | $3.21 | $3.27 | 939.08K |
| Oct 15, 2026 | $3.43 | $3.64 | $3.43 | $3.57 | 793.85K |
| Oct 14, 2026 | $3.39 | $3.615 | $3.345 | $3.43 | 1.04M |
| Oct 13, 2026 | $3.62 | $3.62 | $3.395 | $3.40 | 605.46K |
| Oct 12, 2026 | $3.64 | $3.71 | $3.60 | $3.61 | 603.48K |
| Oct 9, 2026 | $3.53 | $3.65 | $3.42 | $3.645 | 625.76K |
| Oct 8, 2026 | $3.58 | $3.61 | $3.35 | $3.53 | 1.04M |
| Oct 7, 2026 | $3.72 | $3.72 | $3.58 | $3.62 | 515.5K |
| Oct 6, 2026 | $3.60 | $3.84 | $3.60 | $3.79 | 682.82K |
| Oct 5, 2026 | $3.60 | $3.60 | $3.455 | $3.59 | 777.42K |
| Oct 2, 2026 | $3.84 | $3.84 | $3.51 | $3.58 | 1.13M |
| Oct 1, 2026 | $3.85 | $3.91 | $3.79 | $3.79 | 738.9K |
| Sep 30, 2026 | $3.90 | $3.90 | $3.75 | $3.84 | 786.21K |
| Sep 29, 2026 | $3.96 | $3.97 | $3.79 | $3.86 | 645.15K |
| Sep 28, 2026 | $3.89 | $3.995 | $3.68 | $3.96 | 712.7K |
| Sep 25, 2026 | $3.75 | $4.00 | $3.66 | $3.915 | 923.82K |
| Sep 24, 2026 | $3.75 | $3.75 | $3.595 | $3.72 | 1.01M |
| Sep 23, 2026 | $4.14 | $4.14 | $3.735 | $3.76 | 765.64K |
| Sep 22, 2026 | $4.10 | $4.175 | $4.07 | $4.13 | 511.02K |
| Sep 21, 2026 | $4.12 | $4.125 | $4.00 | $4.08 | 776.67K |
Latest LENZ news
The latest Smart Investors Daily articles mentioning LENZ.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LENZ research
Overview
Company profile and research snapshot.
Company profile
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $61.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | Piper Sandler | Neutral | — |
| Aug 12, 2026 | Piper Sandler | Neutral | — |
| Jul 7, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Citigroup | Buy | — |
| May 12, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Sep 4, 2026
LENZ Therapeutics: Still Speculative But Priced For Disasters
LENZ Therapeutics: Strong Buy with $21.3 fair value (~266% upside). Vizz peak sales modeled at $375M amid risks & competition.
Benzinga · Aug 12, 2026
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $12 to $7.
SeekingAlpha · Aug 12, 2026
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsDaniel Chevallard - Chief Financial OfficerEvert...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
